SEC filings and other documents

Symvess expands into dialysis and CABG, with key regulatory and commercial milestones ahead.

Strong clinical results and commercial rebuilding drive growth outlook despite ongoing losses.

Symvess delivers superior outcomes and cost savings in vascular trauma, with a robust clinical pipeline.

ATEV provided superior catheter-free days and fewer infections than AVF in women on dialysis.

All proposals, including director elections and share increase, passed with strong support.

Symvess sales surged, restructuring cut costs, and key clinical milestones are on track for 2026.

ATEV outperformed AV fistula in women with ESKD, reducing catheter dependence and complications.

Strong clinical data and strategic partnerships drive expansion into trauma, dialysis, and coronary markets.

Engineered vessel platform shows clinical, economic, and pipeline momentum across major indications.

Symvess adoption and financials improved in 2025, with strong U.S. and international momentum.

Symvess sales surged in Q3 2025, with expanded hospital adoption and strengthened financial position.

Symvess adoption surged, July sales outpaced H1, and cost cuts target $50M+ savings by 2026.

SYMVESS launch targets trauma centers with strong clinical data and a robust cash runway through 2026.

CIMVEST's commercial launch gains traction, with strong financial and clinical progress in Q1 2025.

SYMVESS launch accelerates with FDA approval, strong hospital uptake, and first commercial sales.